
Karen M Kuntz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/639157/publications.pdf Version: 2024-02-01



KADEN M KUNTZ

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Reevaluating the Evidence for Intensive Postoperative Extracolonic Surveillance for Nonmetastatic Colorectal Cancer. Value in Health, 2022, 25, 36-46. | 0.1 | 1 |
| 2 | A Cost-Effectiveness Evaluation of Surgical Approaches to Proctectomy. Journal of Gastrointestinal Surgery, 2021, 25, 1512-1523. | 0.9 | 9 |
| 3 | The effectiveness and value of novel treatments for cystic fibrosis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 276-280. | 0.5 | 4 |
| 4 | Colorectal Cancer Screening. JAMA - Journal of the American Medical Association, 2021, 325, 1998. | 3.8 | 145 |
| 5 | Return to work after deceased donor kidney transplant under the kidney allocation system. Clinical Transplantation, 2021, 35, e14444. | 0.8 | 0 |
| 6 | Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1510-1518. | 1.4 | 18 |
| 7 | Cost-effectiveness Evaluation of Laparoscopic Versus Robotic Minimally Invasive Colectomy. Annals of Surgery, 2020, 272, 334-341. | 2.1 | 29 |
| 8 | Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio. Pharmacoeconomics, 2020, 38, 285-296. | 1.7 | 4 |
| 9 | Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating Mutation. Value in Health, 2020, 23, 1332-1339. | 0.1 | 4 |
| 10 | Validation of Colorectal Cancer Models on Long-term Outcomes from a Randomized Controlled Trial. Medical Decision Making, 2020, 40, 1034-1040. | 1.2 | 7 |
| 11 | Cost-effectiveness of surveillance with CT colonography after resection of colorectal cancer. BMJ Open Gastroenterology, 2020, 7, e000450. | 1.1 | 0 |
| 12 | A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer. European Urology Oncology, 2019, 2, 649-655. | 2.6 | 45 |
| 13 | Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. PLoS ONE, 2019, 14, e0220234. | 1.1 | 39 |
| 14 | Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. European Urology, 2019, 75, 910-917. | 0.9 | 34 |
| 15 | Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis. PharmacoEconomics - Open, 2018, 2, 309-323. | 0.9 | 8 |
| 16 | Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer. Gastroenterology, 2018, 154, 105-116.e20. | 0.6 | 26 |
| 17 | Yield and Cost-effectiveness of Computed Tomography Colonography Versus Colonoscopy for Post Colorectal Cancer Surveillance. MDM Policy and Practice, 2018, 3, 238146831881051. | 0.5 | 4 |
| 18 | Cost-effectiveness of spinal manipulation, exercise, and self-management for spinal pain using an individual participant data meta-analysis approach: a study protocol. Chiropractic & Manual Therapies, 2018, 26, 46. | 0.6 | 5 |

Karen M Kuntz

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Future Directions for Cost-effectiveness Analyses in Health and Medicine. Medical Decision Making, 2018, 38, 767-777. | 1.2 | 58 |
| 20 | Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis. Journal of Urology, 2018, 200, 1215-1220. | 0.2 | 36 |
| 21 | Effects of cognition, function, and behavioral and psychological symptoms on outâ€ofâ€pocket medical and nursing home expenditures and time spent caregiving for persons with dementia. Alzheimer's and Dementia, 2017, 13, 801-809. | 0.4 | 34 |
| 22 | Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis. Pharmacoeconomics, 2017, 35, 1073-1085. | 1.7 | 9 |
| 23 | Societal and Family Lifetime Cost of Dementia: Implications for Policy. Journal of the American Geriatrics Society, 2017, 65, 2169-2175. | 1.3 | 113 |
| 24 | The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Seminars in Arthritis and Rheumatism, 2017, 46, 594-600. | 1.6 | 67 |
| 25 | Authors' response. Journal of the American Dental Association, 2016, 147, 231. | 0.7 | 0 |
| 26 | Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses. JAMA - Journal of the American Medical Association, 2016, 316, 1093. | 3.8 | 2,149 |
| 27 | Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies. JAMA - Journal of the American Medical Association, 2016, 315, 2595. | 3.8 | 388 |
| 28 | Cost-Effectiveness of Integrating a Clinical Decision Rule and Staged Imaging Protocol for Diagnosis of Appendicitis. Value in Health, 2016, 19, 28-35. | 0.1 | 32 |
| 29 | Validation of Models Used to Inform Colorectal Cancer Screening Guidelines. Medical Decision Making, 2016, 36, 604-614. | 1.2 | 52 |
| 30 | A restricted look at CRC screening: not considering annual stool testing as an option. American Journal of Managed Care, 2016, 22, e270-4. | 0.8 | 0 |
| 31 | Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis. Journal of Alzheimer's Disease, 2015, 47, 729-740. | 1.2 | 9 |
| 32 | Optimal Colorectal Cancer Screening in States' Low-Income, Uninsured Populations-The Case of South Carolina. Health Services Research, 2015, 50, 768-789. | 1.0 | 16 |
| 33 | Perceptions of Contralateral Breast Cancer Risk: A Prospective, Longitudinal Study. Annals of Surgical Oncology, 2015, 22, 3846-3852. | 0.7 | 22 |
| 34 | Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling. Medical Decision Making, 2015, 35, 584-595. | 1.2 | 43 |
| 35 | Response. Journal of the National Cancer Institute, 2015, 107, djv093-djv093. | 3.0 | 0 |
| 36 | The Comparative Safety of Tumor Necrosis FactorÂInhibitors in Rheumatoid Arthritis: AÂMeta-analysis Update of 44 Trials. American Journal of Medicine, 2014, 127, 1208-1232. | 0.6 | 100 |

Karen M Kuntz

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Survival Outcomes After Contralateral Prophylactic Mastectomy: A Decision Analysis. Journal of the National Cancer Institute, 2014, 106, dju160-dju160. | 3.0 | 88 |
| 38 | Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia. Value in Health, 2014, 17, 310-319. | 0.1 | 16 |
| 39 | Derivation of Background Mortality by Smoking and Obesity in Cancer Simulation Models. Medical Decision Making, 2013, 33, 176-197. | 1.2 | 13 |
| 40 | Linear Regression Metamodeling as a Tool to Summarize and Present Simulation Model Results. Medical Decision Making, 2013, 33, 880-890. | 1.2 | 40 |
| 41 | Secular Trends in Colon and Rectal Cancer Relative Survival. Journal of the National Cancer Institute, 2013, 105, 1806-1813. | 3.0 | 76 |
| 42 | State-Transition Modeling. Medical Decision Making, 2012, 32, 690-700. | 1.2 | 231 |
| 43 | Modeling Good Research Practices—Overview. Medical Decision Making, 2012, 32, 667-677. | 1.2 | 389 |
| 44 | Clarifying Differences in Natural History between Models of Screening. Medical Decision Making, 2011, 31, 540-549. | 1.2 | 45 |
| 45 | A Systematic Comparison of Microsimulation Models of Colorectal Cancer. Medical Decision Making, 2011, 31, 530-539. | 1.2 | 96 |
| 46 | Stool DNA Testing to Screen for Colorectal Cancer in the Medicare Population. Annals of Internal Medicine, 2010, 153, 368. | 2.0 | 73 |
| 47 | Cost-Effectiveness of Computed Tomographic Colonography Screening for Colorectal Cancer in the Medicare Population. Journal of the National Cancer Institute, 2010, 102, 1238-1252. | 3.0 | 125 |